Cancer & Oncology This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Find the best Christmas presents and January Sales in the UK with this simple shopping directory.

• Default
• News
• Research
• Blogs
• Podcasts
• Video
• Events
• Funding
• Alerts
• Clinical Trials
• Forums
• Top 20

Investigation of the cumulative body burden of estrogen-3,4-quinone in breast cancer patients and controls using albumin adducts as biomarkers.
Abstract Both 17β-estradiol-2,3-quinone (E(2)-2,3-Q) and 17β-estradiol-3,4-quinone (E(2)-3,4-Q)are reactive metabolites of estrogen. Elevation of E(2)-3,4-Q to E(2)-2,3-Q ratio is thought to be an important indicator of estrogen-induced carcinogenesis. Our current study compared the cumulative body burden of these estrogen quinones in serum samples taken from Taiwanese women with breast cancer (n=152) vs healthy controls (n=75) by using albumin (Alb) adducts as biomarkers. Results clearly demonstrated the presence of cysteinyl adducts of E(2)-2,3-Q-4-S-Alb and E(2)-3,4-Q-2-S-Alb in all study population at levels ...
Source: Toxicology Letters - February 16, 2013 Category: Toxicology Authors: Lin C, Chen DR, Hsieh WC, Yu WF, Lin CC, Ko MH, Juan CH, Tsuang BJ, Lin PH Tags: Toxicol Lett Source Type: research

Target organ toxicities in studies conducted to support first time in man dosing: an analysis across species and therapy areas.
Abstract An analysis of target organ toxicities in first time in man (FTiM) toxicity studies for 77 AstraZeneca candidate drugs (CDs) was conducted across a range of therapy areas. In the rodent, the most frequently affected organ was the liver followed by adrenal glands, kidney, spleen, bone marrow and thymus. In non-rodent, liver and thymus were the most frequently affected organs, followed closely by the testis and GI tract. The profile of affected organs was largely similar across the therapy areas of respiratory and inflammation, cardiovascular/gastrointestinal and CNS/pain. The oncology/infection therapy area...
Source: Regulatory Toxicology and Pharmacology : RTP - February 16, 2013 Category: Toxicology Authors: Horner S, Ryan D, Robinson S, Callander R, Stamp K, Roberts R Tags: Regul Toxicol Pharmacol Source Type: research

Mesenchymal stem cell-like cells from children foreskin inhibit human gastric cancer SGC-7901 cell line growth.
In this study, we isolated and identified human mesenchymal stem cell-like cells from foreskin (hFMSCs) by explant culture. HFMSCs had similar morphology and immunophenotype to that of human bone marrow derived-mesenchymal stem cells. HFMSCs formed colonies after 9days of inoculation and could be propagated for more than 50 passages. HFMSCs had a normal karyotype and high G0/G1 phase independent of passage number. Further, hFMSCs could be induced to differentiate into osteocytes and adipocytes. We found that the growth of SGC-7901(human gastric adenocarcinoma) cells could be suppressed by simultaneous injection of hFMSCs i...
Source: Experimental and Molecular Pathology - February 16, 2013 Category: Pathology Authors: Li Y, Zhao Y, Cheng Z, Zhan J, Sun X, Qian H, Zhu W, Xu W Tags: Exp Mol Pathol Source Type: research

[Cervical lymphatic metastasis of an intracranial meningioma].
CONCLUSIONS. Metastatic meningioma is a rare cause of neck mass, but should be considered in any patient with a history of meningioma, especially if the tumor has histological features of malignant behavior. The present case demonstrates the aggressive biologic potential of an intracranial meningioma, with potential for distant spread and lymphatic invasion. PMID: 23400650 [PubMed - in process]
Source: Revista de Neurologia - February 16, 2013 Category: Neurology Authors: Rico-Cotelo M, Prieto-Gonzalez A, Reyes-Santias RM, Diaz-Cabanas L, Martin-Martin C Tags: Rev Neurol Source Type: research

Exposure to flame retardant chemicals on commercial airplanes
Conclusion: This study adds to the limited body of knowledge regarding exposure to flame retardants on commercial aircraft, an environment long hypothesized to be at risk for maximum exposures due to strict flame retardant standards for aircraft materials. Our findings indicate that flame retardants are widely used in many airplane components and all airplane types, as expected. Most flame retardants, including TDCPP, were detected in 100% of dust samples collected from the airplanes. The concentrations of BDE 209 were elevated by orders of magnitude relative to residential and office environments.
Source: Environmental Health - February 16, 2013 Category: Environmental Health Authors: Joseph AllenHeather StapletonJose VallarinoEileen McNeelyMichael McCleanStuart HarradCassandra RauertJohn Spengler Source Type: research

Clinical Characteristics and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck
ConclusionsAge, DM, tumor site, histologic grade, and stage were independently significant prognostic factors for ACCHN. In addition, an adequate dose of postoperative radiotherapy can improve local control and DFS of patients with ACCHN. Level of Evidence2b. Laryngoscope, 2013
Source: The Laryngoscope - February 16, 2013 Category: ENT & OMF Authors: Yunsuk Choi, Sung‐Bae Kim, Dok Hyun Yoon, Ji Youn Kim, Sang‐wook Lee, Kyung‐Ja Cho Tags: Head and Neck Source Type: research

Invasive Fungal Rhinosinusitis
ConclusionsDSS and OS remain low for patients with AIFR. Extensive surgical resection in patients with these poor prognostic signs should be considered carefully in light of their poor survival. Long‐term survivors are at significant risk of sinonasal complications and should be followed closely. Level of Evidence4. Laryngoscope, 2012
Source: The Laryngoscope - February 16, 2013 Category: ENT & OMF Authors: Marcus M. Monroe, Max McLean, Nathan Sautter, Mark K. Wax, Peter E. Andersen, Timothy L. Smith, Neil D. Gross Tags: Allergy/Rhinology Source Type: research

Solitary Pulmonary Nodule
Your doctor found a solitary pulmonary nodule on your chest x-ray. What is the definition of solitary pulmonary nodule?
Source: About.com Lung Cancer - February 16, 2013 Category: Cancer & Oncology Authors: lungcancer.guide at about.com Tags: health Source Type: news

diarrhea
Every one of us has suffered diarrhea at some point in our lives. This uncomfortable symptom of watery, frequent stools is commonly the result of viral, bacterial or parasitic disease, but can also occur due to chronic bowel diseases like Crohn's. Learn when to call your doctor and when to treat this symptom at home.
Source: About.com Colon Cancer - February 16, 2013 Category: Cancer & Oncology Authors: coloncancer.guide at about.com Tags: health Source Type: news

Specific PPAR gamma agonists may have different effects on cancer incidence
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Bambury, R. M., Iyer, G., Rosenberg, J. E. Tags: letters to the editor Source Type: research

Preoperative PET/CT in early-stage breast cancer: is the TNM classification enough?
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Gilardi, L., Fumagalli, L., Paganelli, G. Tags: letters to the editor Source Type: research

Clinical complete response in locally advanced rectal cancer: can we offer a wait-and-see policy?
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Hernandez-Garcia, I., Viudez, A., Suarez, J., Arias De la Vega, F., Vera, R. Tags: letters to the editor Source Type: research

Reply to 'preoperative PET/CT in early-stage breast cancer: is the TNM classification enough?'
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Bernsdorf, M. Tags: letters to the editor Source Type: research

Biology matters: the clinical impact of single-receptor discordance on breast cancer
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Farolfi, A., Ibrahim, T., Scarpi, E., Amadori, D. Tags: letters to the editor Source Type: research

Socio-demographic inequalities in stage of cancer diagnosis: evidence from patients with female breast, lung, colon, rectal, prostate, renal, bladder, melanoma, ovarian and endometrial cancer
Conclusions There are substantial socio-demographic inequalities in stage at diagnosis for most cancers. Earlier detection interventions and policies can be targeted on patients at higher risk of advanced stage diagnosis.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Lyratzopoulos, G., Abel, G. A., Brown, C. H., Rous, B. A., Vernon, S. A., Roland, M., Greenberg, D. C. Tags: cancer prevention Source Type: research

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy
Conclusion We found EGFR aberrations in 1.6% of a large group of patients with diverse tumors other than NSCLC, and treatment with an EGFR inhibitor could be associated with prolonged SD.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Wheler, J. J., Falchook, G. S., Tsimberidou, A. M., Hong, D. S., Naing, A., Piha-Paul, S. A., Chen, S. S., Fu, S., Stephen, B., Fok, J. Y., Janku, F., Kurzrock, R. Tags: clinical trials Source Type: research

Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma?
Conclusion Even if patients with adjuvant PORT were at higher risk of recurrence, there was a trend for radiotherapy (RT) to decrease the local relapse rate and improve recurrence-free survival. This study confirms that adjuvant conformal RT should be evaluated in a randomized trial, the control arm being FAS. Adjuvant RT in the preoperative setting is being evaluated in an EORTC trial.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Le Pechoux, C., Musat, E., Baey, C., Al Mokhles, H., Terrier, P., Domont, J., Le Cesne, A., Laplanche, A., Bonvalot, S. Tags: sarcomas Source Type: research

Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE
Conclusion This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Thariat, J., Schouman, T., Brouchet, A., Sarini, J., Miller, R. C., Reychler, H., Ray-Coquard, I., Italiano, A., Verite, C., Sohawon, S., Bompas, E., Dassonville, O., Salas, S., Aldabbagh, K., Maingon, P., de La MotteRouge, T., Kurtz, J. E., Usseglio, J., Tags: sarcomas Source Type: research

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall
Conclusions In this setting of high-risk STS treated by preoperative CT or CT–RT, the negative impact of positive margins on the outcome was limited. When close margins can be anticipated preoperative CT–RT may be a reasonable option to maximize the chance of cure.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Gronchi, A., Verderio, P., De Paoli, A., Ferraro, A., Tendero, O., Majo, J., Martin, J., Comandone, A., Grignani, G., Pizzamiglio, S., Quagliuolo, V., Picci, P., Frustaci, S., Dei Tos, A. P., Palassini, E., Stacchiotti, S., Ferrari, S., Fiore, M., Casali, Tags: sarcomas Source Type: research

Alcohol drinking and all cancer mortality: a meta-analysis
Conclusions This meta-analysis confirms the health hazards of heavy drinking (≥50 g/day) and benefits of light drinking (≤12.5 g/day). Large-sample, well-designed, prospective epidemiological studies, especially on heavy drinking among women, should be developed in future.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Jin, M., Cai, S., Guo, J., Zhu, Y., Li, M., Yu, Y., Zhang, S., Chen, K. Tags: epidemiology Source Type: research

Adolescents with acute lymphoblastic leukemia treated at pediatric versus adult hospitals
Conclusions Using population-based data, AYA ALL patients had similar outcomes whether treated at a pediatric or an adult center. Early introduction of aggressive treatment protocols in adult centers may have negated differences in outcomes among AYA patients by site of care.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Pole, J. D., Alibhai, S. M. H., Ethier, M. C., Teuffel, O., Portwine, C., Zelcer, S., Johnston, D. L., Silva, M., Alexander, S., Brandwein, J. M., Sung, L. Tags: epidemiology Source Type: research

European cancer mortality predictions for the year 2013
Conclusions Favourable trends will continue in 2013. Pancreatic cancer has become the fourth cause of cancer death in both sexes, while in a few years lung cancer will likely become the first cause of cancer mortality in women as well, overtaking breast cancer.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C., Negri, E. Tags: epidemiology Source Type: research

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors
Conclusion AVE1642 was tolerable with 75–100 mg/m2 docetaxel and 1000 mg/m2 gemcitabine/75 mg erlotinib, achieving durable disease control in 44%, with an association between IGF-II and response.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Macaulay, V. M., Middleton, M. R., Protheroe, A. S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.- Y., LoRusso, P., Mery-Mignard, D., Soria, J.- C. Tags: phase I and pharmacokinetics Source Type: research

ARIX: A randomised trial of acupuncture v oral care sessions in patients with chronic xerostomia following treatment of head and neck cancer
Conclusion Eight sessions of weekly group acupuncture compared with group oral care education provide significantly better relief of symptoms in patients suffering from chronic radiation-induced xerostomia.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Simcock, R., Fallowfield, L., Monson, K., Solis-Trapala, I., Parlour, L., Langridge, C., Jenkins, V., on behalf of the ARIX Steering Committee Tags: head and neck cancer Source Type: research

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation
Conclusions TNFerade™ Biologic can be safely integrated with FHX chemoradiotherapy at an MTD of 4 x 1010 PU. Monitoring for thrombotic events is indicated.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Seiwert, T. Y., Darga, T., Haraf, D., Blair, E. A., Stenson, K., Cohen, E. E. W., Salama, J. K., Villaflor, V., Witt, M. E., Lingen, M. W., Weichselbaum, R. R., Vokes, E. E. Tags: head and neck cancer Source Type: research

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
Conclusions Dacomitinib demonstrated clinical activity in RM-SCCHN, and the primary end point of this study was met. The toxicity profile of this agent was generally manageable with dose interruptions and adjustments.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Abdul Razak, A. R., Soulieres, D., Laurie, S. A., Hotte, S. J., Singh, S., Winquist, E., Chia, S., Le Tourneau, C., Nguyen-Tan, P.- F., Chen, E. X., Chan, K. K., Wang, T., Giri, N., Mormont, C., Quinn, S., Siu, L. L. Tags: head and neck cancer Source Type: research

Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
Conclusions The results of the present study may indicate that the ABCG 421C>A genetic polymorphism influences the MMR of imatinib in patients with CML.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Seong, S. J., Lim, M., Sohn, S. K., Moon, J. H., Oh, S.- J., Kim, B. S., Ryoo, H. M., Chung, J. S., Joo, Y. D., Bang, S. M., Jung, C. W., Kim, D. H., Park, S. Y., Yoon, S. S., Kim, I., Lee, H. G., Won, J. H., Min, Y. H., Cheong, J. W., Park, J. S., Eom, K Tags: hematologic malignancies Source Type: research

Early development of the metabolic syndrome after chemotherapy for testicular cancer
Conclusions The current data suggest that the MS occurs at earlier age in TC survivors treated with chemotherapy compared with controls and is accompanied by early signs of atherosclerosis. As low testosterone may have a causal role, it is a target for interventions.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: de Haas, E. C., Altena, R., Boezen, H. M., Zwart, N., Smit, A. J., Bakker, S. J. L., van Roon, A. M., Postma, A., Wolffenbuttel, B. H. R., Hoekstra, H. J., van Leeuwen, F. E., Sleijfer, D. T., Gietema, J. A. Tags: urogenital tumors Source Type: research

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
Conclusion IHC using the VE1 clone is a specific and sensitive method for the detection of BRAFV600E and may be an alternative to molecular biology for the detection of mutations in NSCLC.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Ilie, M., Long, E., Hofman, V., Dadone, B., Marquette, C. H., Mouroux, J., Vignaud, J. M., Begueret, H., Merlio, J. P., Capper, D., von Deimling, A., Emile, J. F., Hofman, P. Tags: lung cancer Source Type: research

The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
Conclusions miR-21, miR-155 and miR-101 showed significant differences in invasive versus non-invasive IPMNs. miR-21 emerged as an independent prognostic biomarker in invasive IPMNs and should be validated in prospective studies.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Caponi, S., Funel, N., Frampton, A. E., Mosca, F., Santarpia, L., Van der Velde, A. G., Jiao, L. R., De Lio, N., Falcone, A., Kazemier, G., Meijer, G. A., Verheul, H. M., Vasile, E., Peters, G. J., Boggi, U., Giovannetti, E. Tags: gastrointestinal tumors Source Type: research

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors
Conclusion Assessment of the Her2/neu status in tissue biopsies carries a significant risk of sampling errors, thereby rendering patients unsuitable for treatment with trastuzumab.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Warneke, V. S., Behrens, H.- M., Boger, C., Becker, T., Lordick, F., Ebert, M. P. A., Rocken, C. Tags: gastrointestinal tumors Source Type: research

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07
Conclusions The addition of panitumumab to neoadjuvant CRT in patients with KRAS wild-type LARC resulted in a high pNC/CR rate, mostly grade 3 DC. The results of both treatment arms exceeded prespecified thresholds. The addition of panitumumab increased toxicity.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Helbling, D., Bodoky, G., Gautschi, O., Sun, H., Bosman, F., Gloor, B., Burkhard, R., Winterhalder, R., Madlung, A., Rauch, D., Saletti, P., Widmer, L., Borner, M., Baertschi, D., Yan, P., Benhattar, J., Leibundgut, E. O., Bougel, S., Koeberle, D. Tags: gastrointestinal tumors Source Type: research

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
Conclusions In this study, PFS and ORR were estimated to be similar with AMG 386 plus CX and placebo plus CX treatment. Compared with placebo, toxicity of AMG 386 plus CX was greater but manageable. Previous presentation The results of this study have not been previously published or submitted for publication elsewhere. The results were presented in part at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 20–22, 2011. Clinical trial registration ClinicalTrials.gov registration number: NCT00583674
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.- N., Zhong, Z. D., Bass, M. B., Adewoye, A. H., Bodoky, G. Tags: gastrointestinal tumors Source Type: research

Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report
Conclusions Addition of bevacizumab to peri-operative ECX chemotherapy is feasible with acceptable toxicity and no negative impact on surgical outcomes.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Okines, A. F. C., Langley, R. E., Thompson, L. C., Stenning, S. P., Stevenson, L., Falk, S., Seymour, M., Coxon, F., Middleton, G. W., Smith, D., Evans, L., Slater, S., Waters, J., Ford, D., Hall, M., Iveson, T. J., Petty, R. D., Plummer, C., Allum, W. H. Tags: gastrointestinal tumors Source Type: research

A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status
Conclusions A risk classification system comprising the immunohistochemical expression of three proteins (Apc, Fhit, and Her2) and five clinicopathological parameters (stage, resected nodes, margins, location, and sex) accurately separates the resected gastric cancer patients into three classes of risk.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Bria, E., De Manzoni, G., Beghelli, S., Tomezzoli, A., Barbi, S., Di Gregorio, C., Scardoni, M., Amato, E., Frizziero, M., Sperduti, I., Corbo, V., Brunelli, M., Bersani, S., Tortora, G., Scarpa, A. Tags: gastrointestinal tumors Source Type: research

Prospective analysis of vitamin D and endometrial cancer risk
Conclusion Both predicted 25(OH)D and total dietary vitamin D intake were not associated with endometrial cancer incidence. These results suggest that vitamin D may not protect against the development of endometrial cancer. However, the low and narrow vitamin D exposure range in the cohort may limit generalizability of the results.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Liu, J. J., Bertrand, K. A., Karageorgi, S., Giovannucci, E., Hankinson, S. E., Rosner, B., Maxwell, L., Rodriguez, G., De Vivo, I. Tags: gynecologic tumors Source Type: research

A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG
Conclusions Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe. However, it provided no improvement in PFS or OS compared with flat dosing. Baseline neutrophils over-ride nadir counts in prognostic significance. These data may have wider implications particularly in respect of the management of chemotherapy-induced neutropenia.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Banerjee, S., Rustin, G., Paul, J., Williams, C., Pledge, S., Gabra, H., Skailes, G., Lamont, A., Hindley, A., Goss, G., Gilby, E., Hogg, M., Harper, P., Kipps, E., Lewsley, L.-A., Hall, M., Vasey, P., Kaye, S. B. Tags: gynecologic tumors Source Type: research

Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane
Conclusion Even with a clinical and biochemical profile compatible with menopause, switching from tamoxifen to an AI should be avoided in patients <48 with CIA.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Guerrero, A., Gavila, J., Folkerd, E., Ortiz, B., Martinez, F., Garcia, A., Climent, M. A., Guillem, V., Ruiz, A. Tags: breast cancer Source Type: research

The role of radioactive iodine-125 seed localization in breast-conserving therapy following neoadjuvant chemotherapy
Conclusions BCT after NAC can be carried out successfully after initial localization with I-125 seeds in both unifocal and multifocal breast tumors with complete resection rates of >90%.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Gobardhan, P. D., de Wall, L. L., van der Laan, L., ten Tije, A. J., van der Meer, D. C. H., Tetteroo, E., Poortmans, P. M. P., Luiten, E. J. T. Tags: breast cancer Source Type: research

Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse
Conclusions PgR loss identifies Luminal B breast cancer subgroups at higher risk of relapse and death, both with HER-2-positive and HER-2-negative disease.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Cancello, G., Maisonneuve, P., Rotmensz, N., Viale, G., Mastropasqua, M. G., Pruneri, G., Montagna, E., Iorfida, M., Mazza, M., Balduzzi, A., Veronesi, P., Luini, A., Intra, M., Goldhirsch, A., Colleoni, M. Tags: breast cancer Source Type: research

Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients
Conclusions The pathological assessment of tumor response might provide stronger prognostic information in LABC patients.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Romero, A., Garcia-Saenz, J. A., Fuentes-Ferrer, M., Lopez Garcia-Asenjo, J. A., Furio, V., Roman, J. M., Moreno, A., de la Hoya, M., Diaz-Rubio, E., Martin, M., Caldes, T. Tags: breast cancer Source Type: research

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement
Conclusions The IMPAKT 2012 Working Group proposed the following recommendations: (i) a need to develop models that integrate clinicopathologic factors along with genomic tests; (ii) demonstration of clinical utility should be made in the context of a prospective randomized trial; and (iii) the creation of registries for patients who are subjected to genomic testing in the daily practice.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Azim, H. A., Michiels, S., Zagouri, F., Delaloge, S., Filipits, M., Namer, M., Neven, P., Symmans, W. F., Thompson, A., Andre, F., Loi, S., Swanton, C. Tags: breast cancer Source Type: research

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
Conclusion The EPclin score is able to predict favorable prognosis in a majority of patients that clinical guidelines would assign to intermediate or high risk. EPclin may reduce the indications for chemotherapy in ER-positive postmenopausal women with a limited number of clinical risk factors.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Dubsky, P., Filipits, M., Jakesz, R., Rudas, M., Singer, C. F., Greil, R., Dietze, O., Luisser, I., Klug, E., Sedivy, R., Bachner, M., Mayr, D., Schmidt, M., Gehrmann, M. C., Petry, C., Weber, K. E., Kronenwett, R., Brase, J. C., Gnant, M., on behalf of t Tags: breast cancer Source Type: research

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy
Conclusions Our results suggest that mRNA levels of ESR1 and HER2 predict response to neoadjuvant chemotherapy and are significantly associated with long-term outcome. As an additional option to standard immunohistochemistry and gene-array-based analysis, quantitative RT-PCR analysis might be useful for determination of the receptor status in breast cancer.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Denkert, C., Loibl, S., Kronenwett, R., Budczies, J., von Torne, C., Nekljudova, V., Darb-Esfahani, S., Solbach, C., Sinn, B. V., Petry, C., Muller, B. M., Hilfrich, J., Altmann, G., Staebler, A., Roth, C., Ataseven, B., Kirchner, T., Dietel, M., Untch, M Tags: breast cancer Source Type: research

Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients
Conclusions In this small pilot biomarker study ancillary to the PACS01 trial, the GGI outperforms the prognostic performance of centrally determined HG, MAI, Ki67 IHC status and mRNA expression. Further validation is warranted in larger series.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Bertucci, F., Finetti, P., Roche, H., Le Doussal, J. M., Marisa, L., Martin, A. L., Lacroix-Triki, M., Blanc-Fournier, C., Jacquemier, J., Peyro-Saint-Paul, H., Viens, P., Sotiriou, C., Birnbaum, D., Penault-Llorca, F. Tags: breast cancer Source Type: research

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
Conclusion RS-guided chemotherapy decision-making resulted in a substantial modification of adjuvant chemotherapy usage in node-negative and node-positive ER+ EBC.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Eiermann, W., Rezai, M., Kummel, S., Kuhn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J. Tags: breast cancer Source Type: research

A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma
Conclusion Overweight and obesity are strongly related to EGCA, particularly to espophageal adenocarcinoma.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Turati, F., Tramacere, I., La Vecchia, C., Negri, E. Tags: reviews Source Type: research

Female fertility loss and preservation: threats and opportunities
Conclusion Patient awareness, physician knowledge, early counseling, costs management, international registry, interdisciplinary networks, and research development are necessary to improve the current care in the field of female fertility preservation.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Salama, M., Winkler, K., Murach, K. F., Seeber, B., Ziehr, S. C., Wildt, L. Tags: reviews Source Type: research

From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF)
Conclusions Individual screening requires rigorous assessment and precise research in order to potentially develop a lung-cancer screening policy.
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Couraud, S., Cortot, A. B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappe, P., Ferretti, G. R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.- P. Tags: reviews Source Type: research

From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident d...
Source: Annals of Oncology - February 16, 2013 Category: Cancer & Oncology Authors: Thomas, A., Rajan, A., Lopez-Chavez, A., Wang, Y., Giaccone, G. Tags: reviews Source Type: research